

Prior Authorization DRUG Guidelines

LETAIRIS (ambrisentan)

Effective Date: 10/20/14

Date Developed: 10/14/14

Last Approval Date: 01/26/16, 01/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

Description: Letairis is an endothelin receptor antagonist selective for the endothelin type-A (ETA) receptor. This prevents the action of a potent paracrine peptide on the ETA receptor which leads to vasodilation.

Authorization Criteria: Pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group I to improve exercise ability and delay clinical worsening.

Dosing: 5mg once daily, up to maximum of 10 mg daily

How Supplied: Tablets 5mg and 10mg

Contraindications/Warnings: Contraindicated in pregnancy; avoid grapefruit

Major Adverse Reactions: Pulmonary edema with pulmonary veno-occlusive disease (PVOD); decreased sperm count; decreased hemoglobin; fluid retention

Major Drug Interactions: Use caution with other vasodilators

REFERENCES

1. Badesch DB, Abman SH, Simonneau G, et al, "Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines," *Chest*, 2007, 131(6):1917-28.
2. Galie N, Badesch D, Oudiz R, et al, "Ambrisentan Therapy for Pulmonary Arterial Hypertension," *J Am Coll Cardiol*, 2005, 46(3):529-35.
3. Langleben D, "Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension," *Clin Chest Med*, 2007, 28(1):117-25.
4. *Letairis* (ambrisentan) [package insert]. Foster City, CA: Gilead; May 2014
5. McLaughlin VV, Archer SL, Badesch DB, et al, "ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association," *J Am Coll Cardiol*, 2009, 53(11):1573-619. [

6. Vatter H and Seifert V, “Ambrisentan, a Non-peptide Endothelin Receptor Antagonist,” *Cardiovasc Drug Rev*, 2006, 24(1):63-76
7. www.uptodate.com: Ambrisentan: Drug Guidelines

Revision History:

Date Approved by P&T Committee: 10/28/14; QA Committee: 11/25/14

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check MCG